Resolutions at Aerocrine’s Extraordinary General Meeting
An Extraordinary General Meeting (EGM) was held in Aerocrine AB (NASDAQ OMX Stockholm: AERO) on 16 November 2011 in Stockholm. The EGM resolved to approve the proposal by the Board of Directors on the implementation of a long-term incentive program (LIP 2011) and the issuance and approval of transfer of warrants. Thomas Eklund was elected new member of the Board.
LIP 2011 is, among other things, part of Aerocrine’s strategy to build and strengthen the company’s U.S. operations and commercial organization. In brief, under LIP 2011 a total of not more than 10,000,000 employee stock options (ESOs) will be allotted free of charge to approximately 80 current and, in addition thereto, future senior executives and other employees within the group as well as other key persons, including scientific and clinical consultants. The ESOs will entitle to the acquisition of shares in Aerocrine. In order to enable the delivery of shares and otherwise safeguard the fulfillment of Aerocrine’s obligations under LIP 2011, the EGM resolved on the issuance of not more than 8,648,461 warrants to the wholly-owned subsidiary Aerocrine ESOP AB and approved that the warrants, as well as part of the warrants issued in conjunction with the implementation of Aerocrine’s 2007 and 2009 incentive programs, may be transferred and disposed of under LIP 2011.
The meeting also resolved to elect Thomas Eklund new member of the Board. As previously announced, Karl Swartling stepped down from the Board in conjunction with the EGM.
For complete information regarding the resolutions by the EGM, please visit www.aerocrine.se where documentation related to the EGM is available for download.
For more information, contact:
Anders Williamsson, Chairman of the Board, telephone +46 708 721 865.
About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 a.m. on November 17, 2011.